hrcak mascot   Srce   HID

Pregledni rad

LIRAGLUTIDE IN THE TREATMENT OF DIABETES TYPE 2

Branko Novak
Željko Metelko

Puni tekst: hrvatski, pdf (298 KB) str. 0-0 preuzimanja: 118* citiraj
APA 6th Edition
Novak, B. i Metelko, Ž. (2011). LIRAGLUTID U LIJEČENJU ŠEĆERNE BOLESTI TIPA 2. Liječnički vjesnik, 133 (7-8), 0-0. Preuzeto s https://hrcak.srce.hr/171841
MLA 8th Edition
Novak, Branko i Željko Metelko. "LIRAGLUTID U LIJEČENJU ŠEĆERNE BOLESTI TIPA 2." Liječnički vjesnik, vol. 133, br. 7-8, 2011, str. 0-0. https://hrcak.srce.hr/171841. Citirano 19.10.2019.
Chicago 17th Edition
Novak, Branko i Željko Metelko. "LIRAGLUTID U LIJEČENJU ŠEĆERNE BOLESTI TIPA 2." Liječnički vjesnik 133, br. 7-8 (2011): 0-0. https://hrcak.srce.hr/171841
Harvard
Novak, B., i Metelko, Ž. (2011). 'LIRAGLUTID U LIJEČENJU ŠEĆERNE BOLESTI TIPA 2', Liječnički vjesnik, 133(7-8), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171841 (Datum pristupa: 19.10.2019.)
Vancouver
Novak B, Metelko Ž. LIRAGLUTID U LIJEČENJU ŠEĆERNE BOLESTI TIPA 2. Liječnički vjesnik [Internet]. 2011 [pristupljeno 19.10.2019.];133(7-8):0-0. Dostupno na: https://hrcak.srce.hr/171841
IEEE
B. Novak i Ž. Metelko, "LIRAGLUTID U LIJEČENJU ŠEĆERNE BOLESTI TIPA 2", Liječnički vjesnik, vol.133, br. 7-8, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171841. [Citirano: 19.10.2019.]

Sažetak
Diabetes type 2 is the most frequent metabolic disorder in Croatia, and also in all developed countries as well as in most of the countries in development. Chronic complications of diabetes are significant contributors to the morbidity in the population, and their management consumes a considerable amount of financial health resources. Previous treatment possibilities showed limited results in reducing the frequency of chronic complications and their consequences. Advancement in medical knowledge provides better understanding of etiology and pathogenesis of diabetes type 2, allowing as well a development of the new categories of drugs. Liraglutide is a representative of a new drug class which shows significant advantages over former medications.

Ključne riječi
Glucagon-like peptide 1 – analogs and derivatives, pharmacology, therapeutic use, administration and dosage; Diabetes mellitus, type 2 – drug therapy; Hypoglycemic agents – therapeutic use

Hrčak ID: 171841

URI
https://hrcak.srce.hr/171841

[hrvatski]

Posjeta: 241 *